Post-cataract surgery intraocular injections offer alternative to traditional drop therapy

With more than 3 million procedures performed annually in the U.S., cataract surgery is nearly a rite of passage. Technological advances including phacoemulsification and premium IOLs have all contributed to making cataract surgery one of the safest and most effective procedures performed. However, the post-surgical drop regimen has remained a largely unchanged and cumbersome process for both patients and office staff.As an “in the trenches” surgeon working to provide the best care for my patients, I believe the time has arrived to confidently adopt the practice of administering post-surgical pharmacological treatment intraocularly. Patients benefit from the convenience and affordability, and my staff is relieved of many of the calls we receive from patients and pharmacies. To best serve the needs of my patients, I adopted Tri-Moxi-Vanc therapy (Imprimis Pharmaceuticals) into my surgical armamentarium. The compounded medication consists of a proprietary formulation of triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin in a sterile package. The product is ordered from an accredited compounding pharmacy and delivered directly to the office.